Clean sweep for AbbVie in Humira litigation

Boehringer Ingelheim has become the latest biosimilar maker to resolve litigation over AbbVie’s arthritis treatment Humira (adalimumab).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Boehringer teams up with Gubra to develop second obesity treatment

30 May 2019 German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.

Americas

Abbvie faces multiple Humira antitrust suits

4 April 2019 AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

Americas

AbbVie and Pfizer in Humira licensing deal

3 December 2018 AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More on this story

Big Pharma

Boehringer teams up with Gubra to develop second obesity treatment

Americas

Abbvie faces multiple Humira antitrust suits

4 April 2019 AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

Americas

AbbVie and Pfizer in Humira licensing deal

3 December 2018 AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

More on this story

Big Pharma

Boehringer teams up with Gubra to develop second obesity treatment

Americas

Abbvie faces multiple Humira antitrust suits

4 April 2019 AbbVie is now facing six antitrust class-action lawsuits which claim that the company illegally stopped competition for its arthritis treatment Humira.

Americas

AbbVie and Pfizer in Humira licensing deal

3 December 2018 AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.